Allergan to launch eyelash growth stimulator

By Katie Bird

- Last updated on GMT

Related tags: Jan marini, Clinical trial, Vice president, Market, Allergan

Pharmaceutical giant Allergan plans to release an eyelash growth
stimulator having recently fought a number of alleged patent
infringement cases over the drug.

The release of the treatment depends on approval of the application by the FDA and if successful the company believes the product would be available sometime in 2009. Allergan's drug is based on bimatoprost, a synthetic prostaglandin analogue - the eyelash enhancing qualities of which were discovered during its use as a glaucoma treatment. Clinial trials​ According to the company a clinical trial program has been completed demonstrating that the formulation, when applied directly to the base of the eyelashes, results in significant growth. "We are pleased with the results of our clinical program and believe this innovative product, if approved, could meet a significant and currently unmet demand in the medical aesthetic marketplace,"​ said Allergan's executive vice president of research and development Scott Whitcup. Allergan estimates this market to be significant, anticipating sales exceeding $500m per year. Allergen fights patent infringement​ With this kind of market it comes as no surprise that Allergan has fought hard to protect bimatoprost and its analogues in a number of alleged patent infringement cases. California-based Jan Marini Skin Research was one of the companies accused by Allergan, which marketed an eyelash growth enhancing product that the pharmaceutical manufacturer claimed was based on bimatoprost. Jan Marini refuted the claims but nonetheless removed the product from the market. Marini Lash​ Last week the company released its latest lash enhancing offering, Marini Lash. This is described as a 'non prostaglandin' peptide blend which CEO Jan Marini said is 'an entirely new technology that yields phenomenal results'. Marini cited continued customer demand as a driver behind the new release saying that although previous products had been removed from the market demand was still ever present. "There was never an ebb in interest. We were still inundated with inquiries on our web site"​ she said, as quoted by the Wall Street Journal.

Related topics: Market Trends, Color Cosmetics

Related news

Show more

Related products

show more

CameleonCaps™ win Silver @ In-Cos MakeUp Bar!

CameleonCaps™ win Silver @ In-Cos MakeUp Bar!

Tagra Biotechnologies | 29-Apr-2019 | Product Brochure

CameleonCaps™ are cellulose-based encapsulated pigments that are durable during formulation and scale-up, yet break easily beneath fingertips upon application....

US to EU cosmetics export – product compliance

US to EU cosmetics export – product compliance

TSG Consulting | 03-Sep-2018 | Technical / White Paper

The EU market can be highly lucrative for US cosmetics companies. However, it’s vital that the requirements of EU Cosmetics Regulation 1223/2009 are properly...

HS-cartoon-610x343

Equivalent Performance in Spreadability and Dry feel

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 10-May-2018 | Product Brochure

Today consumers expect high levels of performance from their personal care products, but they also want to make socially responsible product choices: products...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars